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ABSTRACT (249, max 250 words) 
Objective: Few studies have described mortality and clinical outcomes after myocardial 
infarction (MI) in the HIV-positive population. This study evaluated changes in short-
term mortality after MI in HIV-positive individuals in the D:A:D Study, and 
investigated possible reasons for any changes seen. 
Design: Prospective cohort study. 
Methods: Demographic, cardiovascular disease (CVD)/HIV-related characteristics and 
CVD-related interventions (invasive cardiovascular procedures and drug interventions) 
were summarised at the time of and following an MI. Associations between calendar 
year and mortality in the first month after MI were identified using logistic regression 
with adjustment for confounders, including interventions received in the first month 
after MI. 
Results: 1008 HIV-positive individuals experiencing an MI over the period 1999-2014 
were included. The absolute number of MIs decreased from 214 (1999-2002) to 154 
(2011-2014). Whilst the CVD risk profile remained high over time, the HIV status 
improved. The use of CVD-related interventions after MI appeared to increase over 
time. The proportion of individuals who died in the first month after MI dropped from 
26.6% in 1999-2002 to 8.4% in 2011-2014.  Later calendar year was associated with 
decreased short-term mortality; this effect was attenuated after adjusting for CVD-
related interventions received in the first month after MI (odds ratio changed from 0.88 
[95% confidence interval 0.83, 0.93] to 0.97 [0.91, 1.02]).  
Conclusions: Improvements in short-term survival after MI appear to be largely driven 
by improved medical management of CVD risk in HIV-positive individuals after MI. 
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Efforts are still needed to treat CVD risk factors and increase access to CVD-related 
interventions. 
 
Key words: Cardiovascular disease, myocardial infarction, HIV infection, 
cardiovascular interventions, mortality 
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INTRODUCTION 
The mortality rate after a first myocardial infarction (MI) has declined in individuals of all 
ages in the general population over the past 25 years1 2. This improvement is mainly 
attributable to better management of cardiovascular disease (CVD) risk factors and the 
increased use of recommended medical therapies and invasive cardiovascular procedures 
(ICPs)1 2. It is well documented that HIV-positive persons have a higher risk of CVD; 
multiple factors, not all of which are fully explained, may contribute to development of 
atherosclerosis in this population. The  prevalence of many traditional CVD risk factors (e. g 
smoking, dyslipidemia) is higher in HIV-positive persons than in the general population3  4.  
Although some studies have reported an improvement over the years5, earlier findings from 
the D:A:D Study demonstrated that the CVD risk profile of individuals living with human 
immunodeficiency virus (HIV) in the cohort generally worsened from 1999-20066. In 
addition, exposure to some antiretroviral (ARV) drugs has been shown to be associated with 
an increased risk of MI7 8 9 10 11 12. Furthermore, the increased CVD risk noted in HIV-
positive individuals may also be related to HIV-related chronic inflammation and 
immunosuppression10 8 13 14 15 16. Whilst incidence rates of MI in the HIV-positive population 
are higher than in the HIV-negative population17 18 13, there has been a decrease in the rate 
over time in the D:A:D Study, likely as a result of a more aggressive targeted approach to the 
management of CVD risk factors6. Recent studies have also reported a decreasing trend to the 
excess MI risk in HIV-positive people compared to the general population in later years19 20. 
Examples of independent predictors of increased mortality after MI in the general population 
include older age, male gender, in-hospital cardiac complications and no ICP after MIs21. 
Previous findings have shown that HIV-positive individuals admitted for acute coronary 
syndromes faced a substantial short-term risk of death and an increased risk of coronary 
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revascularization, recurrent MI22 and all-cause mortality one year after MI23. However, few 
studies have described mortality and clinical outcomes after MI in the HIV-positive 
population and changes in such outcomes over time. The primary objective of this study was 
to investigate changes over time in short-term mortality after MI in HIV-positive participants 
in the D:A:D Study, and possible explanations for any changes seen. 
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MATERIAL AND METHODS 
The D:A:D (Data on Adverse events of antiretroviral Drugs) study is a large, prospective 
observational cohort study which follows >49,000 HIV-positive persons from 11 
collaborating cohorts in Europe, USA and Australia; to date, these persons have contributed 
>350,000 person-years of follow-up. The primary aim is to investigate associations between 
the use of ARV drugs and risk of CVD7. The data include information on socio-demographic 
factors, acquired immunodeficiency syndrome (AIDS) events, CD4 count, HIV viral load 
(VL), other laboratory results, ARV-regimen/ treatment history and CVD risk factors/ 
treatments. Data are reported to the D:A:D coordinating centre as anonymous, computerized 
case report files and then merged into a standardized central dataset. All cases of MI are 
validated centrally using criteria from the WHO MONICA Study24 and classified using a 
Dundee score24 as definite, possible or unclassifiable and further distinguished into non-fatal 
and fatal events. In addition, ICPs (coronary artery bypass graft (CABG), carotid angioplasty 
(ANG) and carotid endarterectomy (END)) are reported. Information on causes of death is 
collected using a designated Coding of Causes of Death in HIV (CoDe) form 
(www.chip.dk/code)25. This analysis was conducted in accordance with the Declaration of 
Helsinki and approved by national ethical committee where necessary.    
Statistical methods 
All individuals experiencing an MI during prospective follow-up from study initiation in 
1999 to February 1st, 2014 were identified. Demographic, HIV/CVD-related characteristics 
and the use of CVD interventions (ICPs, receipt of anti-platelets, angiotensin-converting 
enzyme inhibitors (ACEIs), other anti-hypertensives (including beta-blockers) and lipid-
lowering drugs (LLDs)) were described at the time of the MI and over the follow-up period. 
Mortality after MI was described using Kaplan-Meier methods, with follow-up on individuals 
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who remained alive being right-censored six months after their last clinic visit or on 1st 
February 2014, whichever was earlier. Only the first MI that occurred over follow-up was 
considered for each individual (although some individuals had experienced their first ever MI 
prior to enrolment in the study).   
Factors associated with overall mortality and mortality from the first month after MI onwards 
were identified using Cox Proportional Hazards regression models. Factors (measured at the 
time of MI) that were considered for inclusion in these models were: age, gender, mode of 
HIV acquisition, ethnicity, cohort, calendar year of MI, current/cumulative exposure to ARVs, 
prior AIDS diagnosis, CD4 count, VL, smoking status, body mass index, family history of 
CVD, hypertension (systolic blood pressure >140 mm Hg and/or diastolic blood pressure >90 
mm Hg and/or on ACEIs or other anti-hypertensives26), dyslipidaemia (total cholesterol (TC) 
>6.2 mmol/L or hyperdensity lipoprotein cholesterol (HDL-C) <0.9 mmol/L or TC:HDL-C 
ratio >6.5 or receipt of LLDs26), prior diabetes, prior stroke (both centrally validated), prior 
MI and Framingham risk score. Factors that were associated with mortality in univariable 
analyses (p<0.1) were considered for inclusion in the multivariable model with a stepwise 
selection procedure used to identify the factors that would be retained in the model. The 
resulting model was then further adjusted for interventions received in the first month after 
MI.   
Factors associated with short-term mortality (deaths occurring within the first 31 days after 
MI) were identified using unadjusted/adjusted logistic regression models with potential 
confounders selected as described above. All models included calendar year as this was our 
exposure of interest; analyses were restricted to individuals with at least one month of follow-
up (or those who had died within the first month) to avoid introducing bias due to variable 
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follow-up times over this first month. Analyses were performed separately for CVD/non-
CVD related deaths and stratified by calendar period. 
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RESULTS 
Characteristics of individuals at time of an MI  
1008 D:A:D participants experienced an MI over the period 1999-2014. The majority were 
men (90.8%), the median (interquartile range [IQR]) age at the time of MI was 51 [44, 58] 
years, and 55.9% were of white ethnicity. The most prevalent CVD risk factors seen were 
dyslipidemia (66.6%), current smoking (53.3%) and hypertension (42.5%); around 1 in 3 
individuals with an MI were known to be receiving LLDs (35.5%) and 1 in 4 (26.4%) anti-
hypertensives. At the time of MI, 90.4% of the individuals were on ARV treatment with only 
2.7% being ARV-naïve (the remaining 6.9% had previously received ARV treatment). The 
median [IQR] 10-year predicted CVD risk (based on the Framingham score, available in 
82.1% of those with an MI) was 14.1% [8.9%, 20.7%]; 58.2% of the individuals with an 
available score had a moderate to high predicted risk of >10% (Table 1). 
The number of MIs in each year is shown in Table 1. The proportion of MIs in each year that 
was classified as definite MIs was stable (58.9% in 1999-2002 to 60.4% in 2011-2014). There 
were some changes in the characteristics of individuals that experienced an MI over the same 
period; the median age increased from 48 years to 54 years, the proportion of current smokers 
increased from 49.5% to 54.6%, and there were increases in the proportions of individuals 
who had dyslipidemia, hypertension and a moderate/high Framingham risk score. In more 
recent years, a higher proportion of individuals were on ARV therapy, had a suppressed VL 
and a higher CD4 count (Table 1). 
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Interventions at or after time of MI  
Overall, 581 (57.6%) of the study participants underwent an angioplasty, 87 (8.6%) a CABG 
and 7 (0.7%) an endarterectomy following their MI, with 620 (61.5%) of participants 
undergoing at least one ICP after MI. Just under two-thirds, 370 (59.7%) of the ICPs were 
carried out on the same day as the MI, 168 (27.1%) were carried out within the first 31 days 
and the remaining 82 (13.2%) were carried out more than 31 days after MI. LLDs were 
initiated after MI in 397 of 650 participants (61.1%) who were not already receiving them, 
with 254 (63.9%) of these initiating LLDs within the first month after MI; anti-platelets, 
ACEIs and anti-hypertensives were initiated in 477 of 758 participants (62.9%) (362 (75.9%) 
within the first month after MI), 354 of 810 participants (43.7%) (202 (57.1%) within the first 
month after MI) and 399 of 742 participants (53.8%) (265 (66.5%) within the first month 
after MI), respectively. In general, there seemed to be an increasing trend over time in the use 
of medical interventions prior to MI and in all interventions after MI (Figure 1).  
Causes of death following MI 
Over a median [IQR] follow-up time of 42.7 [9.6, 84.0] months after their MI, 117 of the 
1008 HIV-positive individuals (11.6%) experienced a further MI and 339 (33.6%) died. 
Of the deaths that occurred, 145 (42.8% of deaths, 14.4% of all individuals) were on the same 
day as the MI, 37 (10.7% of deaths, 3.7% of all individuals) were within the first month after 
the MI, and 157 (46.3% of deaths, 15.6% of all individuals) were more than 31 days after MI.  
The proportion of deaths that were due to CVD varied according to the timing of the death 
relative to the MI: 129 (89%) and 33 (87.1%) of deaths that occurred on the same day as the 
MI or within the first month after MI were due to CVD respectively, whereas only 59 
(37.6%) of deaths that occurred >31 days after MI were due to CVD (Figure 2a). In total, 182 
deaths occurred in the first month after MI yielding an overall short-term mortality rate of 
8 
 
 
18.1%; this rate dropped from 26.6% in 1999-2002 to 8.4% in 2011-2014. The overall 
proportion of individuals dying from any CVD dropped from 72.6% in 1999-2002 to 40.9% 
in 2011-2014, whereas the proportion of individuals dying from causes other than CVD 
following their MI increased over the same period; major contributing causes being 
HIV/AIDS, non-AIDS cancers, bacterial infections, lung disease and unknown causes (Figure 
2b).   
Factors associated with overall mortality following MI 
In unadjusted proportional hazards regression models, factors associated with increased 
mortality were: older age; injection drug use (IDU) mode of HIV acquisition; black African 
ethnicity; prior AIDS; higher VL; diabetes; prior MI; and prior stroke. Higher CD4 count, 
later calendar year of MI and family history of CVD were all associated with decreased 
mortality (data not shown). In a multivariable model, all these factors remained 
independently associated with mortality except black African ethnicity, prior AIDS and 
higher VL. 
In order to investigate the potential impact of interventions received in the first month post-
MI, the analysis was repeated after excluding individuals who did not survive or remain 
under follow-up beyond the first month. Factors remaining independently associated with 
mortality in this multivariable model were: older age; prior AIDS; higher VL; previous MI; 
diabetes; and later calendar year (Table 2). Additional adjustment for the interventions 
received in the first month had only minor effects on the associations between these factors 
and mortality, although it led to an attenuation of the calendar year association from hazard 
rate (HR) 0.95 [95% confidence interval (CI) 0.89, 1.00] per later year to 0.98 [95% CI 0.92, 
1.04] per later year (Table 2). Of the interventions themselves, only the ICPs demonstrated a 
strong association with mortality in this model.  
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Factors associated with short-term mortality following MI 
In unadjusted logistic regression models, the factors associated with an increased risk of 
short-term mortality were: IDU mode of HIV acquisition; black African ethnicity; prior 
AIDS; higher VL and prior stroke. A family history of CVD, higher CD4 count and later 
calendar year were associated with decreased risk of short-term mortality (data not shown). In 
a multivariable model excluding interventions during the first month after MI, IDU mode of 
HIV acquisition, higher CD4 count, family history of CVD and prior stroke continued to be 
associated with short-term mortality, and again there was a strong calendar year effect (Table 
3). When including interventions received in the first month following MI, ICPs, LLDs and 
anti-platelets were significantly associated with decreased risk of short-term mortality, and 
this led to attenuations of the associations with prior stroke (from odds ratio (OR) 3.24 [95% 
CI 1.61, 6.53] to 2.08 [95% CI 0.90, 4.84]) and family history of CVD (from 0.46 [95% CI 
0.25, 0.86] to 0.61 [95% CI 0.30, 1.24]). The calendar year effect was attenuated from 0.88 
[95% CI 0.83, 0.93] to 0.97 [95% CI 0.91, 1.02] in this adjusted model (Table 3). 
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DISCUSSION 
We observed an improvement in survival after MI in the D:A:D cohort over the last 15 years. 
Those who experienced an MI continued to be individuals with a high CVD risk profile, 
although their HIV-related health indicators improved. There was an increase in the use of 
interventions at the time of, and shortly after an MI, and we observed a reduction in the short-
term mortality rate following MI. Predictors of decreased short-term mortality were higher 
CD4 count, family history of CVD, later year of MI and the receipt of anti-platelets, LLDs 
and ICPs. When adjusting for CVD interventions in the first month after MI, the calendar 
year effect on short term-mortality was attenuated, arguing that the observed change is 
mainly driven by the increased use of interventions in recent years.   
Within the D:A:D Study, we have seen a gradual reduction in the risk of MI over time in line 
with findings from the general population27, and in the present study, we observed some 
changes in the characteristics of individuals experiencing an MI. As previously 
documented28, the key demographic characteristics in individuals at the time of MI were male 
gender and older age, and other CVD risk factors were dominated by modifiable factors, i.e. 
current smoking, hypertension and dyslipidemia. There were notable increases in the 
proportions of people with an MI who were known to have dyslipidemia and/or hypertension, 
and slight increases in the proportions of individuals with a moderate to high Framingham 
risk score. Most likely this reflects improved monitoring of lipids and blood pressure in the 
cohorts rather than any change over time in the risk conferred by these conditions, as well as 
increased awareness and monitoring of CVD risk and gradual aging of individuals in the 
cohort, respectively. These findings are consistent with earlier studies6 15 29 30 31. The 
proportion of individuals with an MI who were on ARV therapy with a suppressed VL 
increased, as did the median CD4 cell count. This improvement in HIV-related health indices 
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amongst participants in the study has probably contributed to the improved survival seen over 
the study period. The use of improved ARV drugs with fewer metabolic side effects in recent 
years may also partly explain the improved survival, although we did not specifically 
investigate this in our study. 
The HIV-positive population has changed significantly over the last decade as HIV/AIDS-
related morbidity and mortality rates have declined and other causes of death have become 
increasingly common32  33  34. The all-cause mortality rate in the D:A:D Study population fell 
from 17.5 /1000 person-years (PYRS) in 1999/2000 to 9.1 /1000 PYRS in 2009-2011; the 
leading causes of death being AIDS-and HIV-related causes, non-AIDS defining cancers, 
liver disease and CVD32. The crude CVD incidence mortality rate fell from 1.8 /1000 PYRS 
to 0.9 /1000 PYRS from 1999-201132. In this analysis, nearly 90% of individuals who died 
within the first month after MI died of CVD-related causes. Athough the short-term mortality 
rates after MI dropped, our findings emphasise the importance of continued improvement of 
the management of CVD in HIV-positive individuals. The magnitude of the reduction in 
short-term mortality after MI over time in this study (26.6 % to 8.4%) is similar to the 
reductions seen in the general population over the last 15-20 years, although mortality is still  
higher in our study population compared to equally young HIV-negative individuals (< 65 
years)1. 
The clear improvements in survival outcomes in our study, particularly short-term mortality 
in the month following MI, appeared to be largely driven by improved clinical management. 
The use of ICPs increased by 35% from 1999-2002 to 2011-2014 ; where ICPs were used, 
angioplasties in particular tended to be undertaken on the same day as the MI. In some 
studies, HIV-positive individuals have previously been found to have a higher rate of 
recurrent MIs and to more frequently undergo urgent angioplasties18 28 35 36 37 . The 
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proportion of recurrent MIs in the study was 11.6%; which is higher compared to previous 
findings from the general population (8.9% in 2010)38. We were unable to systematically 
evaluate the type of MI and degree of vessel disease, but the relatively young median age of 
the study participants at the time of MI may indicate that a higher proportion may have had a 
ST-elevated myocardial infarction (STEMI), as an inverse relationship has been 
demonstrated in men in the general population between age and the likelihood of the MI 
being a STEMI39. A STEMI often require urgent invasive treatment, possibly partly 
explaining the increased use of ICPs seen, and the latter may also be explained by the 
improvement in HIV-related characteristics, increasing the eligibility of individuals to 
undergo ICPs than was the case in earlier years.  
We reported an increasing trend in the use of certain drugs following MI over time; LLDs and 
anti-platelets were the drugs most frequently started in those not already on these 
medications, arguing that secondary medical prophylaxis of CVD seem to be somewhat 
improving. The effectiveness and quality of CVD drugs may have also improved in more 
recent years, possibly contributing to improved survival. 
In our study, we found that the calendar year effect on decreased short-term mortality seemed 
to be mediated through the increased use of CVD interventions in recent years, as its effect 
was attenuated after adjusting for interventions received in the first month after MI. 
Adjustment for interventions did not influence the decreased short-term mortality risk 
associated with a higher CD4 count. Similarly, adjustment for interventions received in the 
first month after MI also resulted in an attenuation of the calendar effect on long-term 
mortality, again suggesting that this effect was mediated through the use of interventions. 
Adjusting for interventions in the first month following MI did, however, not influence the 
predictors of increased long-term mortality, whereas the associations between stroke, family 
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history of CVD  and IDU mode of HIV acquisition and short-term mortality were weakened, 
suggesting also these associations to be partly influenced by the use of interventions.  
One study previously demonstrated that HIV status influences long-term risk for adverse 
outcomes after MI by being an independent predictor for long-term risk of heart failure40. In 
our study, we were unable to assess the impact of HIV per se, but found that survival 
substantially improved in line with improvements in the CD4 count, which was an 
independent predictor for decreased short-term mortality.  The current longer-term outcomes 
after MI need to be further explored in our study population.   
Although we demonstrated that an increased number of HIV-positive individuals now receive 
invasive and medical interventions after MI, there is still a proportion of individuals surviving 
their MIs who do not appear to receive these interventions. One possible explanation is 
under- or delayed ascertainment of such interventions. However, findings from our annual 
monitoring process suggest that the number of missed clinical events in the D:A:D Study is 
very low. Complicating co-morbidities influencing the eligibility of a person to undergo 
ICPs, the type of MI, and differences in clinical practices at different medical centres may 
also play a role. Further, the use of drug interventions in those with HIV is often challenging 
given the possibility of drug-drug interactions with ARV drugs6 41, which may limit CVD 
treatment options. Finally, previous findings have reported that there is a inverse relationship 
between in-hospital mortality after MI and the number of CVD risk factors present at the time 
of MI42, indicating that low-risk individuals may therefore have other, as yet unidentified, 
factors which may contribute to progressive disease42.   
Some limitations to our study need to be acknowledged. The use of non-medical 
interventions (e.g dietary advice, advice on smoking cessation or exercise) is not captured 
systematically in the D:A:D Study, and may have contributed to improved survival. Further, 
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it is complicated to evaluate the effect of relatively infrequent interventions, such as the use 
of ICPs, in an observational cohort as analyses of these interventions are likely to be affected 
by time-varying confounding and standard analytical methods are likely to give biased 
estimates. Finally, we did not evaluate the status of interventions at time of any recurrent MI 
although these may also have changed over time. 
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CONCLUSION 
In this study, we demonstrated improvements in short-term survival after MI in HIV-positive 
individuals, which appeared to be largely driven by increased use of drug interventions and 
ICPs. However, some individuals are still not receiving these interventions despite a high 
CVD risk profile. Our findings suggest that preventive measures need to be further explored, 
with targeted focusing on modifiable risk factors including smoking cessation, control of 
hypertension, dyslipidemia and diabetes as well as appropriate choice of ARV drugs. 
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FIGURE LEGENDS 
 
Figure 1: Use of invasive procedures and drug interventions before and in the first month 
after MI, stratified by calendar period  
ACE-inhibitors indicate angiotensin converting enzyme-inhibitors; MI, myocardial infarction 
*Angioplasty, coronary bypass, endarterectomy 
Figure 2:  Causes of death among study participants dying following myocardial infarction  
a) Overall, stratified by timing of death relative to MI, b) Overall, stratified by calendar 
period 
AIDS/HIV indicates acquired immunodeficiency syndrome/human immunodeficiency virus; 
CVDs, cardiovascular diseases; MI, myocardial infarction. *Suicide, psychiatric disease, drug 
overdose, accident/violent death, non-bacterial infections, pancreatitis, renal failure, 
gastrointestinal disease, complications due to diabetes, other known/unknown causes 
†Chronic viral hepatitis B and/or C and liver failure, ‡Other cardiovascular diseases 
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 Table 1: Characteristics of individuals at time of myocardial infarction 
 
Demographic 
characteristics 
 Overall Calendar period 
   1999-2002 2003-2004 2005-2006 2007-2008 2009-2010 2011-2014 
Number of MIs  1008 214 191 153 174 122 154 
Dundee 
classification 
        
 Definite 634 (62.9) 126 (58.9) 125 (65.5) 101 (66.0) 108 (62.1) 81 (66.4) 93 (60.4) 
 Possible 213 (21.1) 45 (21.0) 35 (18.3) 38 (24.8) 47 (27.0) 28 (23.0) 20 (13.0) 
 Unclassifiable 161 (16.0) 43 (20.1) 31 (16.2) 14 (9.2) 19 (10.9) 13 (10.7) 41 (26.6) 
Male gender  915 (90.8) 194  (90.7) 177 (92.7) 137 (89.5) 154 (88.5) 114 (93.4) 139 (90.3) 
Age (years) Median  
(IQR) 
51  
(44, 58) 
48  
(42, 55) 
49  
(42, 58) 
49  
(43, 58) 
52  
(45, 59) 
51  
(46, 58) 
54  
(48, 62) 
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Race         
 White 563 (55.9) 146 (68.2) 100 (52.4) 75 (49.0) 94 (54.0) 66 (54.1) 82 (53.3) 
 Black African 36 (3.6) 13 (6.1) 10 (5.2) 7 (4.6) 3 (1.7) 1 (0.8) 2 (1.3) 
 Other/Unknown 409 (40.6) 55 (5.5) 81 (8.0) 71 (7.0) 77 (7.6) 46 (4.6) 69 (6.8) 
Mode of HIV-
acquisition 
        
 IDU 149 (14.8) 39 (18.2) 29 (15.2) 20 (13.1) 26 (14.9) 15 (12.3) 20 (13.0) 
  MSM 580 (57.5) 115 (53.7) 119 (62.3) 85 (55.6) 96 (55.2) 72 (59.0) 93 (60.4) 
 Heterosexual  219 (21.7) 47 (22.0) 29 (15.2) 20 (13.1) 26 (14.9) 15 (12.3) 20 (13.0) 
 Other/Unknown 60 (6.0) 13 (6.1) 14 (7.3) 9 (5.9) 9 (5.2) 6 (4.9) 9 (5.8) 
HIV-related 
characteristics 
        
AIDS 
 
 
 390 (38.6) 80 (37.4) 68 (35.6) 62 (40.5) 70 (40.2) 52 (42.6)                 58 (37.7) 
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Median CD4 
(cells/mm
3
) 
Median  
(IQR) 
480  
(316, 703) 
398  
(244, 620) 
441  
(300, 627) 
460  
(320, 704) 
438  
(270, 632) 
587  
(400, 770) 
585  
(401, 856) 
HIV RNA (<50 
copies/ml) 
 656 (65.3) 95 (44.6) 107 (56.0) 104 (68.0) 128 (74.0) 95 (78.5) 127 (82.5) 
Currently on 
ARVs 
 911 (90.4) 184 (86.0) 173 (90.6) 137 (89.5) 153 (87.9) 116 (95.1) 148 (96.1) 
ARV naïve  27 (2.7) 5 (2.3) 3 (1.6) 2 (1.3) 10 (5.8) 3 (2.5) 4 (2.6) 
Ever received 
NRTIs 
 980 (97.2) 209 (97.7) 187 (97.9) 151 (98.7) 164 (94.3) 119 (97.5) 150 (97.4) 
Cumulative 
exposure (years) 
-NRTIs 
Median  
(IQR) 
7.8 
(4.9,11.3) 
5.0  
(3.5, 7.0) 
7.4  
(5.6, 9.0) 
8.5  
(5.2, 10.5) 
9.4  
(5.5, 11.8) 
11.0  
(6.7, 13.9) 
12.6 
 (7.0, 15.9) 
Ever received 
NNRTIs 
 
 696 (69.1) 127 (59.4) 124 (64.9) 109 (71.2) 127 (73.0) 91 (74.6) 118 (76.6) 
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Cumulative 
exposure (years) 
-NNRTIs 
Median  
(IQR) 
2.7  
(1.1, 4.8) 
1.5  
(0.7, 2.4) 
2.8  
(1.4, 4.0) 
2.8 
(1.0, 4.2) 
3.2  
(1.2, 5.9) 
3.5  
(1.6, 7.2) 
6.2  
(1.5, 10.7) 
Ever received 
PIs 
 862 (85.5) 191 (89.3) 168 (88.0) 131 (85.6) 144 (82.8) 103 (84.4) 125 (81.2) 
Cumulative 
exposure (years) 
-PIs 
Median  
(IQR) 
4.4  
(2.6, 6.9) 
3.3  
(2.3, 4.3) 
4.6  
(2.8, 6.3) 
5.0 
(2.7, 7.3) 
5.4  
(2.9, 8.8) 
5.6  
(2.6, 10.4) 
6.5  
(3.4, 11.0) 
CVD-related 
characteristics 
        
Smoking         
 Current 537 (53.3) 106 (49.5) 92 (48.2) 82 (53.6) 101 (58.1) 72 (59.0) 84 (54.6) 
 Ex-smoker 242 (24.0) 50 (23.4) 40 (20.9) 36 (23.5) 47 (27.0) 27 (22.1) 42 (27.3) 
 Never 115 (11.4) 19 (8.9) 25 (13.1) 22 (14.4) 19 (10.9) 17 (13.9) 13 (8.4) 
 Unknown 114 (11.3) 39 (18.2) 34 (17.8) 13 (8.5) 7 (4.0) 6 (4.9) 15 (9.7) 
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Family history 
of CVD 
 137 (13.6) 31 (14.5) 27 (14.1) 22 (14.4) 23 (13.2) 16 (13.1) 18 (11.7) 
Framingham 
risk  score >10-
20% 
 586 (58.2) 105 (49.5) 101 (52.9) 87 (56.8) 102  (58.6) 84  (68.9) 107  (79.5) 
BMI (kg/m2)         
 <18 36 (3.6) 5 (2.3) 7 (3.7) 2 (1.3) 10 (5.8) 7 (5.7) 5 (3.3) 
 ≥18 ≤26 495 (49.1) 115 (53.7) 100 (52.4) 79 (51.6) 76 (43.7) 52 (42.6) 73 (47.4) 
 >26 ≤30 129 (12.8) 24 (11.2) 21 (11.0) 20 (13.1) 19 (10.9) 21 (17.2) 24 (15.6) 
 >30   51 (5.1) 11 (5.1) 11 (5.8) 11 (7.2) 10 (5.8) 2 (1.6) 6 (3.9) 
 Unknown 297 (29.5) 59 (27.6) 52 (27.2) 41 (26.8) 59 (33.9) 40 (32.8) 46 (29.9) 
Prior diabetes  144 (14.3) 34 (15.9) 31 (16.2) 23 (15.0) 22 (12.6) 10 (8.2) 24 (15.6) 
Prior stroke   42 (4.2) 12 (5.6) 7 (3.7) 6 (3.9) 6 (3.5) 3 (2.5) 8 (5.2) 
Prior MI  78 (7.7) 26 (12.2) 16 (8.4) 10 (6.5) 11 (6.3) 5 (4.1) 10 (6.5) 
Dyslipidemiaa  671 (66.6) 123 (57.5) 134 (70.2) 94 (61.4) 120 (69.0) 93 (76.2) 107 (69.5) 
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Hypertensionb  428 (42.5) 64 (29.9) 73 (38.2) 60 (39.2) 80 (45.0) 63 (51.6) 88 (57.1) 
TC (mmol/l) Median (IQR) 5.6  
(4.7, 6.5) 
5.7  
(4.7, 6.7) 
5.8  
(4.8, 6.7) 
5.5  
(4.7, 6.3) 
5.5  
(4.7, 6.3) 
5.8  
(5.0, 6.6) 
5.3  
(4.5, 6.2) 
HDL-C 
(mmol/l) 
Median (IQR) 1.1  
(0.9, 1.3) 
1.0  
(0.8, 1.2) 
1.1  
(0.8, 1.3) 
1.1  
(0.9, 1.3) 
1.1  
(0.9, 1.4) 
1.1  
(0.9, 1.3) 
1.1  
(0.9, 1.4) 
Triglycerides 
(mmol/l) 
Median (IQR) 2.2  
(1.4, 3.6) 
2.4  
(1.5, 3.9) 
2.4  
(1.4, 4.4) 
2.2  
(1.5, 4.1) 
2.1  
(1.4, 3.1) 
2.3  
(1.6, 3.6) 
1.9  
(1.2, 3.0) 
 
HIV, human immunodeficiency virus; MI, myocardial infarction; IDU, intravenous drug use; MSM, men who have sex with men; AIDS, acquired immunodeficiency 
syndrome; ARVs, anti-retroviral drugs; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; 
CVD, cardiovascular disease; BMI, body mass index; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol. aTC >6.2 mmol/L, HDL-C<0.9 mmol/L, TC:HDL-C 
ratio >6.5 or receipt of lipid-lowering drugs. bSystolic blood pressure >140 mm Hg, diastolic blood pressure > 90 mm Hg or receipt of anti-hypertensives/angiotensin 
converting enzyme-inhibitors. 
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Figure 1. Use of invasive procedures and drug interventions before and in the first month after MI, stratified by calendar period 
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Figure 2. Causes of death among study participants dying following myocardial 
infarction  
a) Overall, stratified by timing of death relative to MI 
b) Overall, stratified by calendar period 
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Table 2: Factors associated with mortality  following myocardial infarction, conditioned 
on the fact that patient survives for at least one month – multivariable model * 
Factor Excluding interventions 
in first month 
Including interventions 
in first month 
 Hazard rate (95% CI), 
p-value 
Hazard rate (95% CI), 
p-value 
Age                      
(/10 years older) 
 1.18 (1.09, 1.28) 
p=0.0001 
1.13 (1.05, 1.23)  
p=0.002 
AIDS  1.45 (1.05, 2.01) 
p=0.02 
1.42 (1.02, 1.98)  
p=0.04 
CD4 count (/50 
cells/mm3 increment) 
 0.97 (0.94, 1.00) 
p=0.05 
0.96 (0.93, 1.00) 
p=0.03 
HIV RNA (/log10 
increment) 
 1.19 (1.03, 1.38) 
p=0.0001 
1.19 (1.02, 1.38)  
p=0.03 
Previous MI  1.85 (1.14, 3.00) 
p=0.02 
1.63 (1.00, 2.67)  
p=0.05 
Previous 
diabetes 
 2.16 (1.46, 3.19)  
p=0.01 
2.13 (1.43, 3.16) 
p=0.0002 
Year of MI (/ later year) 
 
 
0.95 (0.89, 1.00) 
 p=0.007 
0.98 (0.92, 1.04) 
 p=0.50 
Interventions in first month    
Anti-platelets 
 
n/a 0.72 (0.44, 1.17)  
p=0.18 
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ACE- Inhibitors 
 
n/a 1.07 (0.65, 1.76)  
p=0.80 
Anti-hypertensives 
 
n/a 0.76 (0.45, 1.29)  
p=0.31 
Lipid-lowering drugs n/a 0.93 (0.58, 1.49)  
p=0.76 
ICPs n/a 0.44 (0.31, 0.63) 
p=0.0001 
AIDS indicates acquired immunodeficiency syndrome; MI, myocardial infarction; ACE-inhibitors, angiotensin 
converting enzyme- inhibitors; ICP, invasive cardiovascular procedures *Also adjusted for cohort.
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Table 3: Factors associated with short-term mortality following myocardial infarction –
multivariable model* 
Factor  No adjustment for 
interventions in first 
month 
Adjustment for 
interventions in first 
month 
  Odds ratio (95% CI),   
p-value 
Odds ratio (95% CI), 
p-value 
IDU  1.90 (1.20, 2.99)  
p=0.006 
1.66 (0.98, 2.83) 
p=0.06 
CD4 count (/50 
cells/mm3 increment) 
 0.93 (0.90, 0.96) 
p=0.0001 
0.92 (0.89, 0.96) 
p=0.0001 
Family history of CVD 0.46 (0.25, 0.86)  
p=0.01 
0.61 (0.30, 1.24)  
p=0.17 
Stroke  3.24 (1.61, 6.53)  
p=0.001 
2.08 (0.90, 4.84)  
p=0.09 
Year of MI (/later 
year) 
 0.88 (0.83, 0.93) 
p=0.0001 
0.97 (0.91, 1.02)  
p=0.23 
Interventions in first month   
Anti-platelets 
 
 n/a 0.09 (0.03, 0.31) 
p=0.0001 
ACE- inhibitors  n/a 0.45 (0.12, 1.66) 
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p=0.23 
Anti-hypertensives  n/a 0.25 (0.05, 1.18) 
p=0.08 
Lipid-lowering 
drugs 
 n/a 0.27 (0.08, 0.95) 
p=0.04 
ICPs  n/a 0.07 (0.04, 0.13) 
p=0.0001 
IDU indicates intravenous drug use; CVD, cardiovascular disease; MI, myocardial infarction; ACE-inhibitors, 
angiotensin converting enzyme- inhibitors; ICP, invasive cardiovascular procedures *Also adjusted for cohort. 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 
                          
                    
 
